FDA Approves First Drug for Neurotrophic Keratitis

Share this content:
FDA Approves First Drug for Neurotrophic Keratitis
FDA Approves First Drug for Neurotrophic Keratitis

THURSDAY, Aug. 23, 2018 (HealthDay News) -- Oxervate (cenegermin) has been approved by the U.S. Food and Drug Administration to treat neurotrophic keratitis, a rare degenerative disease of the cornea.

This application received priority review by the FDA and was approved under the designation of orphan drug.

Oxervate, produced as an eyedrop, was evaluated in two clinical studies involving a total of 151 patients with neurotrophic keratitis. Some participants were given Oxervate, while others were given a placebo eye drop. Complete corneal healing was reported among 70 percent of patients treated with Oxervate, compared with 28 percent of those given the placebo, the FDA said.

The most common side effects of the drug included eye pain, ocular hyperemia, eye inflammation, and increased lacrimation.

"While the prevalence of neurotrophic keratitis is low, the impact of this serious condition on an individual patient can be devastating," Wiley Chambers, M.D., an ophthalmologist in the FDA's Center for Drug Evaluation and Research, said in a statement. "In the past, it has often been necessary to turn to surgical interventions; these treatments are usually only palliative in this disease. Today's approval provides a novel topical treatment and a major advance that offers complete corneal healing for many of these patients."

Oxervate is produced by the Italian firm Dompé farmaceutici.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Patient-Reported Outcome Measures May Aid Communication

Patient-Reported Outcome Measures May Aid Communication

Usefulness of PROs varies based on how much doctors value, prioritize, and use them

Negative Attitudes Reported Toward Weight-Loss Surgery

Negative Attitudes Reported Toward Weight-Loss Surgery

Women more likely to think surgery is needed for health, less likely to consider it 'easy way out'

Risk for Hospitalization for Heart Failure Greater With Diabetes

Risk for Hospitalization for Heart Failure Greater With ...

Rate has declined but remains higher in those with type 1 or 2 diabetes than in those without

is free, fast, and customized just for you!




Already a member?

Sign In Now »